Skip to main content
OpenTrials
Completed

NCT Number: NCT02112695

Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study

Abnormal opioid system have been identified in addictive behavior and activity of the opioid system has also shown a strong link with the nutritional balance. A significant increase in endorphin levels was noticed after exercise, proportional to the duration and intensity of this activity. One brain imaging study showed an increase in opioid activity in athletes after endurance training. However , a decrease in opioid tone related to receptor desensitization in the brain has been raised in the sport and it is possible to feel like , the subject must perform physical exercise more frequently . Consequently, in order to deepen the hypothesis of addiction in high-level sport , the brain opioid activity should be assessed pre- training compared to a group of sedentary control subjects .

Preliminary results of a previous study the investigators are conducting on anorexia nervosa (AN ) show abnormalities that appear to be involved in self addiction anorexia nervosa and the regulation of gonadal function. However, the relation of cause and effect between these anomalies and undernutrition remains to be determined . Given the addictive component in the endurance sport and the variability of the nutritional status of its practitioners , evaluation of brain activity in these subjects could provide additional answers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Service d'Endocrinologie - CHU Saint-Etienne

Saint-Etienne, 42055, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For High-level sportswomen :

  • 18-35-year-old
  • High-level sportswomen
  • BMI>19kg/m2
  • Absence of eating disorders
  • In pre-competition period
  • Signature of written consent

For controls :

  • 18-35-year-old
  • Sedentary normal weight women
  • BMI>19kg/m2
  • Normal nutritional markers
  • Absence of eating disorders or other psychiatric or organic diseases

Exclusion criteria

  • Oral contraception
  • Heart failure
  • Neuroleptics, antiparkinson drugs, alpha-methyl-dopa, beta blockers, inhibitors of monoamine oxidase-A or MOA-B, tricyclic antidepressants, selective serotonin reuptake inhibitor, thyme-regulators (lithium), anticonvulsant drugs, codeine, morphine, drugs containing tramadol, dopaminergic drugs

Treatment and study plan

[11C]diprenorphine

Other

3 micrograms [11C]diprenorphine - intravenous use - 1 time

Other names: radiopharmacentical precursor solution

Primary outcomes

  1. [11C]diprenorphine binding potential

    Time frame: 2 weeks

    Value of [11C]diprenorphin binding potential in predifined brains regions. [11C]diprenorphin BP will be evaluated by brain positron emission tomography and MRI exam

Secondary outcomes

  1. correlation [11C]diprenorphine BP

    Time frame: 2 weeks

    Correlation between [11C]Diprenorphine binding potential and plasma endogenous opioid levels

  2. correlation [11C]diprenorphine BP

    Time frame: 2 weeks

    Correlation between [11C]Diprenorphine binding potential and psychometric score evaluating addictive behavior, reward and positive reinforcement

  3. correlation [11C]diprenorphine BP

    Time frame: 2 weeks

    Correlation between [11C]Diprenorphine binding potential and appetite regulating hormones

  4. correlation [11C]diprenorphine BP

    Time frame: 2 weeks

    Correlation between [11C]Diprenorphine binding potential and LH response during GnRH test

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne

Other

Collaborators

  • Ministry of Health, France

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Apr 14, 2014
Registry last updated
Oct 29, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.